IP Library Granted Patent US 10,221,448
Granted Patent B2
US 10,221,448 · App. 15/396,132 · Granted Mar 5, 2019

Selective amplification of overlapping amplicons

Inventors: Zhaohui Wang (Southborough, MA); Gang Song (Newton, MA)
Assignee: Pillar Biosciences Inc.
C12Q1/686
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,221,448
App. No.
15/396,132
Granted
Mar 5, 2019
Kind
B2
Abstract

The present invention relates to a scalable multiplex PCR method that can simultaneously amplify overlapping amplicons without the drawbacks of conventional multiplex PCR. The method selectively amplifying target nucleic acid fragments having an overlapping region. The method comprises the steps of: obtaining a first nucleic acid sequence comprising a first tag t2 and a first forward primer F1, obtaining a second nucleic acid sequence comprising a second tag t1 and a first reverse primer R1, obtaining a third nucleic acid sequence comprising the second tag t1 and a second forward primer F2, obtaining a fourth nucleic acid sequence comprising a third tag t3 and a second reverse primer R2, wherein each primer is a gene-specific primer; performing initial cycles of PCR; and then performing later cycles of PCR at higher annealing temperatures to obtain amplification products.

Claims (21)

1. A method for selectively amplifying target nucleic acid fragments having an overlapping region, comprising the steps of:

(a) obtaining a first nucleic acid sequence comprising a first tag (t2) and a first forward primer (F1) complementary to a first target nucleic acid fragment,

(b) obtaining a second nucleic acid sequence comprising a second tag (t1) and a first reverse primer (R1) complementary to the first target nucleic acid fragment,

(c) obtaining a third nucleic acid sequence comprising the second tag (t1) and a second forward primer (F2) complementary to a second target nucleic acid fragment,

(d) obtaining a fourth nucleic acid sequence comprising a third tag (t3), and a second reverse primer (R2) complementary to the second nucleic acid fragment, wherein the first and the second target nucleic acid fragments have an overlapping region,

(e) mixing the first and the second target nucleic acid fragments, the first, the second, the third, and the fourth nucleic acid sequences, and an effective amount of reagents necessary for performing a polymerase chain reaction (PCR);

(f) cycling the mixture of (e) through denaturing, annealing and primer extension steps of PCR for at least two times, and

(g) cycling the mixture of (f) through denaturing, annealing and primer extension steps of PCR at an annealing temperature higher than that in step (f) to obtain amplification products, wherein the third nucleic acid sequence further comprises a full sequence of R1 or a 5′-end partial sequence of R1 (R1^), in between t1 and F2.

2. The method according to claim 1 , wherein the third nucleic acid sequence further comprises a full sequence of R1, in between t1 and F2.

3. The method according to claim 1 , wherein the third nucleic acid sequence further comprises R1^, in between t1 and F2.

4. The method according to claim 3 , wherein R1^ contains 10-90% of the R1 sequence.

5. The method according to claim 1 , wherein the annealing temperature in step (g) is 2-35° C. higher than the annealing temperature in step (f).

6. The method according to claim 1 , wherein the PCR cycling in step (f) is repeated 2-10 times.

7. The method according to claim 1 , wherein the third tag is the same as the second tag.

8. The method according to claim 6 , further comprising the steps of:

(h) mixing the amplification products from step (g), either treated or untreated, with a first and a second universal PCR primers that bind to t1 and t2 respectively, but do not bind to the first and the second target nucleic acid fragments, and an effective amount of reagents necessary for performing a PCR, and

(i) cycling the mixture of step (h) through denaturing, annealing and primer extension steps of PCR to obtain second amplification products.

9. The method of claim 8 , wherein the products from step (g) is pre-treated by dilution, single-strand exonuclease digestion, purification, or adaptor ligation.

10. The method of claim 3 , wherein R1^ contains 2-40 nucleotides.

11. The method of claim 3 , wherein R1^ contains 4-40 nucleotides.

12. The method of claim 3 , wherein R1^ is 1-5 nucleotides shorter than R1.

Assignments (4)
SECURITY INTEREST Recorded Jan 17, 2025
From: PILLAR BIOSCIENCES, INC.
To: SCOF BLOCKER AIV, L.P.
Reel/Frame 069920/0579 →
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2024
From: ANKURA TRUST COMPANY, LLC
To: PILLAR BIOSCIENCES, INC.
Reel/Frame 067003/0630 →
SECURITY INTEREST Recorded Nov 30, 2023
From: PILLAR BIOSCIENCES, INC
To: ANKURA TRUST COMPANY, LLC
Reel/Frame 065725/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2017
From: WANG, ZHAOHUI; SONG, GANG
To: PILLAR BIOSCIENCES INC.
Reel/Frame 040825/0077 →
Continuity (3)
Continuation In Part 15057343 · Mar 1, 2016
Provisional Application 62129360 · Mar 6, 2015
Related Publication 20170107561A1 · Apr 20, 2017